IE 11 is a very old Browser and it`s not supported on this site
Business Report Performance

Performance/Multi-year comparison

Indexed performance since launch

BB Biotech AG (SIX)-CHF


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

31.03.2022 – 31.03.2023

 

(18.4%)

 

(11.2%)

 

(1.1%)

31.03.2021 – 31.03.2022

 

(16.7%)

 

(23.6%)

 

(13.0%)

31.03.2020 – 31.03.2021

 

63.3%

 

67.9%

 

36.7%

29.03.2019 – 31.03.2020

 

(19.5%)

 

(26.6%)

 

(5.8%)

30.03.2018 – 29.03.2019

 

8.3%

 

11.7%

 

9.5%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2022

 

(24.3%)

 

(11.0%)

 

(9.1%)

2021

 

8.3%

 

(11.5%)

 

3.0%

2020

 

19.3%

 

24.3%

 

15.8%

2019

 

18.5%

 

23.4%

 

23.0%

2018

 

(5.2%)

 

(14.5%)

 

(8.0%)

Cumulated performance

31.03.2023

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(4.4%)

 

(9.2%)

 

(2.7%)

1 year

 

(18.4%)

 

(11.2%)

 

(1.1%)

3 years

 

11.0%

 

13.9%

 

17.6%

5 years

 

(3.2%)

 

(6.6%)

 

21.3%

10 years

 

284%

 

162%

 

150%

since inception 1)

 

2 213%

 

1 820%

 

1 223%

1 09.11.1993

Annualized performance

31.03.2023

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(18.4%)

 

(11.2%)

 

(1.1%)

3 years

 

3.5%

 

4.4%

 

5.5%

5 years

 

(0.6%)

 

(1.4%)

 

3.9%

10 years

 

14.4%

 

10.1%

 

9.6%

since inception 1)

 

11.3%

 

10.6%

 

9.2%

1 09.11.1993

BB BIOTECH AG (XETRA)-EUR


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

31.03.2022 – 31.03.2023

 

(17.4%)

 

(8.6%)

 

1.8%

31.03.2021 – 31.03.2022

 

(9.4%)

 

(17.2%)

 

(5.8%)

31.03.2020 – 31.03.2021

 

58.5%

 

60.7%

 

30.8%

29.03.2019 – 31.03.2020

 

(16.2%)

 

(22.6%)

 

(0.6%)

30.03.2018 – 29.03.2019

 

14.5%

 

17.8%

 

15.3%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2022

 

(19.0%)

 

(6.7%)

 

(4.5%)

2021

 

13.3%

 

(7.8%)

 

7.4%

2020

 

18.1%

 

24.8%

 

16.1%

2019

 

23.4%

 

28.1%

 

27.6%

2018

 

(2.2%)

 

(11.1%)

 

(4.3%)

Cumulated performance

31.03.2023

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(6.8%)

 

(9.4%)

 

(3.3%)

1 year

 

(17.4%)

 

(8.6%)

 

1.8%

3 years

 

18.6%

 

21.7%

 

25.5%

5 years

 

13.8%

 

10.9%

 

43.7%

10 years

 

368%

 

222%

 

206%

since inception 1)

 

1 905%

 

1 581%

 

1 301%

1 10.12.1997

Annualized performance

31.03.2023

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(17.4%)

 

(8.6%)

 

1.8%

3 years

 

5.8%

 

6.8%

 

7.9%

5 years

 

2.6%

 

2.1%

 

7.5%

10 years

 

16.7%

 

12.4%

 

11.8%

since inception 1)

 

12.6%

 

11.8%

 

11.0%

1 10.12.1997

BB BIOTECH AG (MILAN)-EUR


Rolling performance

 

 

SHARE

 

NAV

 

NBI TR

31.03.2022 – 31.03.2023

 

(16.9%)

 

(8.6%)

 

1.8%

31.03.2021 – 31.03.2022

 

(9.1%)

 

(17.2%)

 

(5.8%)

31.03.2020 – 31.03.2021

 

57.6%

 

60.7%

 

30.8%

29.03.2019 – 31.03.2020

 

(14.7%)

 

(22.6%)

 

(0.6%)

30.03.2018 – 29.03.2019

 

13.0%

 

17.8%

 

15.3%

Annual performance

 

 

SHARE

 

NAV

 

NBI TR

2022

 

(19.6%)

 

(6.7%)

 

(4.5%)

2021

 

13.0%

 

(7.8%)

 

7.4%

2020

 

19.7%

 

24.8%

 

16.1%

2019

 

22.6%

 

28.1%

 

27.6%

2018

 

(1.3%)

 

(11.1%)

 

(4.3%)

Cumulated performance

31.03.2023

 

 

SHARE

 

NAV

 

NBI TR

YTD

 

(6.0%)

 

(9.4%)

 

(3.3%)

1 year

 

(16.9%)

 

(8.6%)

 

1.8%

3 years

 

18.9%

 

21.7%

 

25.5%

5 years

 

14.6%

 

10.9%

 

43.7%

10 years

 

369%

 

222%

 

206%

since inception 1)

 

366%

 

288%

 

175%

1 19.10.2000

Annualized performance

31.03.2023

 

 

SHARE

 

NAV

 

NBI TR

1 year

 

(16.9%)

 

(8.6%)

 

1.8%

3 years

 

6.0%

 

6.8%

 

7.9%

5 years

 

2.8%

 

2.1%

 

7.5%

10 years

 

16.7%

 

12.4%

 

11.8%

since inception 1)

 

7.1%

 

6.2%

 

4.6%

1 19.10.2000

Multi-year comparison

 

 

31.03.2023

 

2022

 

2021

 

2020

 

2019

 

 

Market capitalization at the end of the period (in CHF mn)

 

2 767.2

 

3 058.1

 

4 274.1

 

4 107.9

 

3 670.3

 

highchart-toggle

Net Asset Value at the end of the period (in CHF mn)

 

2 276.0

 

2 686.1

 

3 283.5

 

3 887.5

 

3 393.0

 

highchart-toggle

Number of shares (in mn)

 

55.4

 

55.4

 

55.4

 

55.4

 

55.4

 

highchart-toggle

Trading volume (in CHF mn)

 

220.9

 

1 482.0

 

2 101.0

 

2 315.6

 

2 004.2

 

highchart-toggle

Profit/(loss) (in CHF mn)

 

(253.9)

 

(357.8)

 

(404.8)

 

691.2

 

677.4

 

highchart-toggle

Closing price at the end of the period in CHF

 

49.95

 

55.20

 

77.15

 

74.15

 

66.25

 

highchart-toggle

Closing price (G) at the end of the period in EUR

 

50.00

 

56.70

 

74.05

 

68.00

 

61.40

 

highchart-toggle

Closing price (I) at the end of the period in EUR

 

50.30

 

56.50

 

74.40

 

68.50

 

61.00

 

highchart-toggle

Stock performance (incl. distributions) 1)

 

(4.4%)

 

(24.3%)

 

8.3%

 

19.3%

 

18.5%

 

highchart-toggle

High/low share price in CHF

 

60.70/49.95

 

78.15/51.00

 

92.20/73.40

 

74.70/45.44

 

73.20/59.35

 

highchart-toggle

High/low share price in EUR

 

60.60/50.00

 

75.40/49.60

 

86.20/67.80

 

69.00/43.04

 

64.70/52.10

 

highchart-toggle

Premium/(discount) (annual average)

 

20.4%

 

20.5%

 

19.5%

 

9.2%

 

11.8%

 

highchart-toggle

Dividend in CHF

 

N.A.

 

2.85

 

3.85

 

3.60

 

3.40

 

highchart-toggle

Degree of investment (quarterly figures)

 

114.0%

 

112.8%

 

108.6%

 

106.8%

 

109.1%

 

highchart-toggle

Total Expense Ratio (TER) p.a. 2)

 

1.28%

 

1.27%

 

1.22%

 

1.25%

 

1.26%

 

highchart-toggle

1 All figures in CHF %, total return-methodology

2 Based on market capitalization

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer